Arcus Biosciences (RCUS) Gets a Hold from Bank of America Securities
In a report released today, Jason Zemansky from Bank of America Securities maintained a Hold rating on Arcus Biosciences (RCUS – Research ...
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
There's been a notable change in appetite for Arcus Biosciences, Inc. ( NYSE:RCUS ) shares in the week since its ...
Hosted on MSN1d
HC Wainwright & Co. Upgrades Arcus Biosciences (RCUS)
Fintel reports that on February 26, 2025, HC Wainwright & Co. upgraded their outlook for Arcus Biosciences (NYSE:RCUS) from ...
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its ...
Arcus Biosciences upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar upgraded Arcus Biosciences (RCUS) to Buy from Neutral with a price target of $24, up from $18. The ARC-20 ...
Biotechs Highlight 6 Stocks Insiders Are Buying Now
Biotech companies saw the most notable insider purchases of the past week. A Mexican billionaire also continued to build a ...
What is Wedbush’s Estimate for RCUS FY2029 Earnings?
Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...
HC Wainwright Lowers Arcus Biosciences (NYSE:RCUS) Price Target to $18.00
Arcus Biosciences (NYSE:RCUS – Get Free Report) had its price target dropped by equities researchers at HC Wainwright from ...
BioPharma Dive8d
Sanofi reaches consumer health deal; Supernus antidepressant fails study
The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...